Wyeth Reports Earnings Results for the 2007 Fourth Quarter and...( - 2007 Fourth Quarter Worldwide Net ...)

- 2007 Fourth Quarter Worldwide Net Revenue Increased 10% to $5.8 Billion and Reported Diluted Earnings per Share Increased 19% to $0.75. Diluted Earnings per Share, Before Certain Significant Items, Increased 18% to

$0.78 - 2007 Full Year Worldwide Net Revenue Increased 10% to $22.4 Billion and

Reported Diluted Earnings per Share Increased 10% to $3.38. Diluted Earnings per Share, Before Certain Significant Items, Increased 12% to

$3.52 - Seven Product Franchises Surpassed $1.0 Billion in Net Revenue in 2007,

Including Three That Exceeded $2.0 Billion in Net Revenue - 2008 Full Year Pro Forma Diluted Earnings per Share Guidance of $3.35 to

$3.49

MADISON, N.J., Jan. 31 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today reported results for the 2007 fourth quarter and full year ended December 31, 2007. Worldwide net revenue increased 10% to $5.8 billion for the 2007 fourth quarter and 10% to $22.4 billion for the 2007 full year. Excluding the favorable impact of foreign exchange, worldwide net revenue increased 6% for the 2007 fourth quarter and 7% for the 2007 full year.

"Our positive 2007 performance was marked by growth from all three divisions, billion or multi-billion-dollar revenue achievement from seven pharmaceutical product franchises, continued strength in biotech, and contributions from exciting new products like Tygacil(R) and Torisel(TM)," said Bernard Poussot, President and Chief Executive Officer, Wyeth. "Looking ahead, we are hopeful that the momentum generated by our existing franchises will be enhanced by new product approvals later this year. We will also be evaluating our cu
'/>"/>